KR20250004644A - 뮤 오피오이드 수용체 길항제를 사용하여 암 및 다른 상태를 치료하는 방법 - Google Patents

뮤 오피오이드 수용체 길항제를 사용하여 암 및 다른 상태를 치료하는 방법 Download PDF

Info

Publication number
KR20250004644A
KR20250004644A KR1020247033220A KR20247033220A KR20250004644A KR 20250004644 A KR20250004644 A KR 20250004644A KR 1020247033220 A KR1020247033220 A KR 1020247033220A KR 20247033220 A KR20247033220 A KR 20247033220A KR 20250004644 A KR20250004644 A KR 20250004644A
Authority
KR
South Korea
Prior art keywords
inhibitor
mor
cancer
vegf
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247033220A
Other languages
English (en)
Korean (ko)
Inventor
로린 존슨
조나단 모스
데이비드 타가트
Original Assignee
글리식스 모어 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글리식스 모어 인크. filed Critical 글리식스 모어 인크.
Publication of KR20250004644A publication Critical patent/KR20250004644A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247033220A 2022-03-10 2023-03-10 뮤 오피오이드 수용체 길항제를 사용하여 암 및 다른 상태를 치료하는 방법 Pending KR20250004644A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318465P 2022-03-10 2022-03-10
US63/318,465 2022-03-10
PCT/US2023/064088 WO2023173055A2 (en) 2022-03-10 2023-03-10 Methods of treating cancer and other conditions with a mu opioid receptor antagonist

Publications (1)

Publication Number Publication Date
KR20250004644A true KR20250004644A (ko) 2025-01-08

Family

ID=87936037

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033220A Pending KR20250004644A (ko) 2022-03-10 2023-03-10 뮤 오피오이드 수용체 길항제를 사용하여 암 및 다른 상태를 치료하는 방법

Country Status (10)

Country Link
US (1) US20250186423A1 (https=)
EP (1) EP4489866A4 (https=)
JP (1) JP2025508131A (https=)
KR (1) KR20250004644A (https=)
CN (1) CN119584986A (https=)
AU (1) AU2023231655A1 (https=)
CA (1) CA3253916A1 (https=)
IL (1) IL315501A (https=)
TW (1) TW202400158A (https=)
WO (1) WO2023173055A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025137697A1 (en) * 2023-12-21 2025-06-26 Glycyx Mor Inc. Methods, systems, and compositions related to use of mu opioid receptor (mor) antagonists
CN121534059A (zh) * 2024-08-09 2026-02-17 盐野义有限公司 一种治疗帕金森综合征或帕金森病的方法和药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
JP6686013B2 (ja) * 2014-10-17 2020-04-22 サリックス ファーマスーティカルズ，インコーポレーテッド 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
EP3490542A4 (en) * 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
US12053523B2 (en) * 2017-12-13 2024-08-06 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
US11471459B2 (en) * 2018-03-26 2022-10-18 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) Compounds with enhanced anti-tumor effects
US20220125844A1 (en) * 2020-10-23 2022-04-28 The Johns Hopkins University Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy

Also Published As

Publication number Publication date
JP2025508131A (ja) 2025-03-21
TW202400158A (zh) 2024-01-01
EP4489866A2 (en) 2025-01-15
CN119584986A (zh) 2025-03-07
IL315501A (en) 2024-11-01
WO2023173055A2 (en) 2023-09-14
US20250186423A1 (en) 2025-06-12
AU2023231655A1 (en) 2024-10-17
EP4489866A4 (en) 2026-03-11
CA3253916A1 (en) 2023-09-14
WO2023173055A3 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
KR20250004644A (ko) 뮤 오피오이드 수용체 길항제를 사용하여 암 및 다른 상태를 치료하는 방법
CN105705148B (zh) 使用普那布林和紫杉烷的组合的癌症疗法
TW202108165A (zh) 治療癌症之方法
EP2882454B1 (en) Combination therapy for the treatment of glioblastoma
JP7001599B2 (ja) 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法
AU2015314753A1 (en) Human dosing of phosphatase inhibitor
KR102082363B1 (ko) 난소암의 치료를 위한 조합 치료
EA016653B1 (ru) Способы и композиции для ингибирования ангиогенеза
KR20190113955A (ko) 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
EP3915585A1 (en) Therapeutic combinations comprising agonists of ferroptosis for treating proliferative disorders
MX2010012358A (es) Tratamientos para el mieloma multiple.
JP2021130704A (ja) Ａｔ２ｒ活性を調節するための組成物および方法
TW202120086A (zh) 治療癌症之方法
EP3355909B1 (en) Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
US20250186393A1 (en) Treatment of breast cancer with amcenestrant
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
CN116920100A (zh) 一种治疗肿瘤的药物组合物及其应用
US20130096099A1 (en) Method of treating brain cancer
JP2017109987A (ja) ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法
AU2006290437A1 (en) Methods of reducing the severity of oral and gastrointestinal mucositis
CN116327772B (zh) SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法
CN119318654A (zh) 氟达拉滨和替莫唑胺联用在治疗脑胶质瘤中的应用
US20240091193A1 (en) Anti-senescence plant polyphenol drug downregulating senescence-related secretory phenotype and use thereof
EP4085908A1 (en) Pharmaceutical combination for treating tumors and application thereof
JP2026500734A (ja) 医薬組み合わせ、及びその使用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000